Skip to main content

MECANISMOS DE REGULACION EPIGENETICA EN PROCESOS DE DIFERENCIACION MIELOIDE RELEVANTES A ENFERMEDAD AUTOINMUNE

SAF2014-55942-R

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2014
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Secretaría de Estado de Educación, Formación Profesional y Universidades
Beneficiary centre FUNDACIO INSTITUT D INVESTIGACIO BIOMEDICA DE BELLVITGE (IDIBELL)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

IL-4 orchestrates STAT6-mediated DNA demethylation leading to dendritic cell differentiation

  • Vento-Tormo, Roser
  • Company Nevado, Juan
  • Rodríguez Ubreva, Javier
  • de la Rica, Lorenzo
  • Urquiza, José M.
  • Javierre, Biola M.
  • Sabarinathan, Radhakrishnan
  • Luque, Ana
  • Esteller, Manel
  • Aran, Josep M.
  • Álvarez Errico, Damiana
  • Ballestar, Esteban
Background: The role of cytokines in establishing specific transcriptional programmes in innate immune cells has long been recognized. However, little is known about how these extracellular factors instruct innate immune cell epigenomes to engage specific differentiation states. Human monocytes differentiate under inflammatory conditions into effector cells with non-redundant functions, such as dendritic cells and macrophages. In this context, interleukin 4 (IL-4) and granulocyte macrophage colony-stimulating factor (GM-CSF) drive dendritic cell differentiation, whereas GM-CSF alone leads to macrophage differentiation. Results: Here, we investigate the role of IL-4 in directing functionally relevant dendritic-cell-specific DNA methylation changes. A comparison of DNA methylome dynamics during differentiation from human monocytes to dendritic cells and macrophages identified gene sets undergoing dendritic-cell-specific or macrophage-specific demethylation. Demethylation is TET2-dependent and is essential for acquiring proper dendritic cell and macrophage identity. Most importantly, activation of the JAK3-STAT6 pathway, downstream of IL-4, is required for the acquisition of the dendritic-cell-specific demethylation and expression signature, following STAT6 binding. A constitutively activated form of STAT6 is able to bypass IL-4 upstream signalling and instruct dendritic-cell-specific functional DNA methylation changes. Conclusions: Our study is the first description of a cytokine-mediated sequence of events leading to direct gene-specific demethylation in innate immune cell differentiation., This work was supported by grant SAF2014-55942-R from the Instituto de Salud Carlos III, organism adscribed to the Ministerio de Economía y Competitividad and confunded by FEDER funds/ European Regional Development Fund (ERDF)- a way to build Europe and Innovation, and the EU FP7 306000 STATegra project. RVT is supported by a PFIS predoctoral fellowship.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Prostaglandin E2 leads to the acquisition of DNMT3A-dependent tolerogenic functions in human Myeloid-derived suppressor cells

  • Rodríguez-Ubreva, Javier
  • Català-Moll, Francesc
  • Obermajer, Nataša
  • Álvarez-Errico, Damiana
  • Ramirez, Ricardo N.
  • Company, Carlos
  • Vento-Tormo, Roser
  • Moreno-Bueno, Gema
  • Edwards, Robert P.
  • Mortazavi, Ali
  • Kalinski, Pawel
  • Ballestar, Estéban
Myeloid-derived suppressor cells (MDSCs) and dendritic cells (DCs) arise from common progenitors. Tumor-derived factors redirect differentiation from immune-promoting DCs to tolerogenic MDSCs, an immunological hallmark of cancer. Indeed, in vitro differentiation of DCs from human primary monocytes results in the generation of MDSCs under tumor-associated conditions (PGE2 or tumor cell-conditioned media). Comparison of MDSC and DC DNA methylomes now reveals extensive demethylation with specific gains of DNA methylation and repression of immunogenic-associated genes occurring in MDSCs specifically, concomitant with increased DNA methyltransferase 3A (DNMT3A) levels. DNMT3A downregulation erases MDSC-specific hypermethylation, and it abolishes their immunosuppressive capacity. Primary MDSCs isolated from ovarian cancer patients display a similar hypermethylation signature in connection with PGE2-dependent DNMT3A overexpression. Our study links PGE2- and DNMT3A-dependent hypermethylation with immunosuppressive MDSC functions, providing a promising target for therapeutic intervention., This work was supported by grants SAF2014-55942-R and PI16/00132 from Instituto de Salud Carlos III, organisms ascribed to the Ministerio de Economía y Competitividad and cofunded by FEDER funds/European Regional Development Fund (ERDF) - a way to build Europe. The study was also supported by NCI/NIH/HHS (United States) grant P50 CA159981 (RPCI-UPCI Ovarian Cancer SPORE) (to N.O., R.P.E., and P.K.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Inflammatory cytokines shape a changing DNA methylome in monocytes mirroring disease activity in rheumatoid arthritis

  • Rodríguez-Ubreva, Javier
  • Calle-Fabregat, Carlos de la
  • Li, T.
  • Ciudad, Laura
  • Ballestar, M.L.
  • Català-Moll, Francesc
  • Morante-Palacios, O.
  • García-Gómez, Antonio
  • Celis, Raquel
  • Humby, F.
  • Nerviani, A.
  • Martín, J.
  • Pitzalis, C.
  • Cañete, Juan D.
  • Ballestar, Estéban
Objective: Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that mainly targets joints. Monocytes and macrophages are critical in RA pathogenesis and contribute to inflammatory lesions. These extremely plastic cells respond to extracellular signals which cause epigenomic changes that define their pathogenic phenotype. Here, we interrogated how DNA methylation alterations in RA monocytes are determined by extracellular signals. Methods: High-throughput DNA methylation analyses of patients with RA and controls and in vitro cytokine stimulation were used to investigate the underlying mechanisms behind DNA methylation alterations in RA as well as their relationship with clinical parameters, including RA disease activity. Results: The DNA methylomes of peripheral blood monocytes displayed significant changes and increased variability in patients with RA with respect to healthy controls. Changes in the monocyte methylome correlate with DAS28, in which high-activity patients are divergent from healthy controls in contrast to remission patients whose methylome is virtually identical to healthy controls. Indeed, the notion of a changing monocyte methylome is supported after comparing the profiles of same individuals at different stages of activity. We show how these changes are mediated by an increase in disease activity-associated cytokines, such as tumour necrosis factor alpha and interferons, as they recapitulate the DNA methylation changes observed in patients in vitro. Conclusion: We demonstrate a direct link between RA disease activity and the monocyte methylome through the action of inflammation-associated cytokines. Finally, we have obtained a DNA methylation-based mathematical formula that predicts inflammation-mediated disease activity for RA and other chronic immune-mediated inflammatory diseases., We thank CERCA Programme/Generalitat de Catalunya for institutional support. EB was funded by the Spanish Ministry of Economy and Competitiveness (MINECO; grant numbers SAF2014-55942-R and SAF2017-88086-R). JDC was funded by FIS grant (PI17/00993) from Institute of Health Carlos III (ISCIII). JDC, JM and EB are supported by RETICS network grant from ISCIII (RIER, RD16/0012/0013), FEDER 'Una manera de hacer Europa'
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease

  • García-Gómez, Antonio
  • Li, Tianlu
  • Rodríguez-Ubreva, Javier
  • Ciudad, Laura
  • Català-Moll, Francesc
  • Godoy-Tena, Gerard
  • Martín-Sánchez, Montserrat
  • San-Segundo, Laura
  • Muntión, Sandra
  • Morales, Xabier
  • Ortiz-de-Solorzano, Carlos
  • Oyarzabal, Julen
  • San José-Enériz, Edurne
  • Esteller, M.
  • Agirre, Xavier
  • Prósper, Felipe
  • Garayoa, Mercedes
  • Ballestar, Estéban
© The Author(s) 2021., Multiple myeloma (MM) progression and myeloma-associated bone disease (MBD) are highly dependent on bone marrow mesenchymal stromal cells (MSCs). MM-MSCs exhibit abnormal transcriptomes, suggesting the involvement of epigenetic mechanisms governing their tumor-promoting functions and prolonged osteoblast suppression. Here, we identify widespread DNA methylation alterations of bone marrow-isolated MSCs from distinct MM stages, particularly in Homeobox genes involved in osteogenic differentiation that associate with their aberrant expression. Moreover, these DNA methylation changes are recapitulated in vitro by exposing MSCs from healthy individuals to MM cells. Pharmacological targeting of DNMTs and G9a with dual inhibitor CM-272 reverts the expression of hypermethylated osteogenic regulators and promotes osteoblast differentiation of myeloma MSCs. Most importantly, CM-272 treatment prevents tumor-associated bone loss and reduces tumor burden in a murine myeloma model. Our results demonstrate that epigenetic aberrancies mediate the impairment of bone formation in MM, and its targeting by CM-272 is able to reverse MBD., We thank CERCA Program/Generalitat de Catalunya and the Josep Carreras Foundation for institutional support. E.B. was funded by the Spanish Ministry of Science and Innovation (grant numbers SAF2014-55942-R and SAF2017-88086-R), co-funded by FEDER funds/European Regional Development Fund (ERDF)—a way to build Europe, and a Senior Research Award from the Multiple Myeloma Research Foundation (MMRF). C.O.-d.-S. was funded by the Spanish Ministry of Science, Innovation and Universities, under grant RTI2018-094494-B-C22 (MCIU/AEI/FEDER, UE). M.G. received financial support from the Spanish FIS-ISCIII (PI15/02156 and PI19/01384) and FEDER. A.G.G is funded by a postdoctoral contract of the Asociación Española Contra el Cáncer (AECC). F.P. was funded by grants from Instituto de Salud Carlos III (ISCIII), PI17/00701 and PI19/01352, TRASCAN (EPICA and Immunocell), Fundació La Marató de TV3, the Accelerator award CRUK/AIRC/AECC joint funder-partnership, CIBERONC (CB16/12/00489) and co-financed with FEDER funds and Fundación Ramón Areces (PREMAMM).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

IL-4 orchestrates STAT6-mediated DNA demethylation leading to dendritic cell differentiation

  • Vento-Tormo, Roser
  • Company Nevado, Juan
  • Rodríguez Ubreva, Javier
  • de la Rica, Lorenzo
  • Urquiza, José M.
  • Javierre, Biola M.
  • Sabarinathan, Radhakrishnan
  • Luque, Ana
  • Esteller, Manel
  • Aran, Josep M.
  • Álvarez Errico, Damiana
  • Ballestar, Esteban
Background: The role of cytokines in establishing specific transcriptional programmes in innate immune cells has long been recognized. However, little is known about how these extracellular factors instruct innate immune cell epigenomes to engage specific differentiation states. Human monocytes differentiate under inflammatory conditions into effector cells with non-redundant functions, such as dendritic cells and macrophages. In this context, interleukin 4 (IL-4) and granulocyte macrophage colony-stimulating factor (GM-CSF) drive dendritic cell differentiation, whereas GM-CSF alone leads to macrophage differentiation. Results: Here, we investigate the role of IL-4 in directing functionally relevant dendritic-cell-specific DNA methylation changes. A comparison of DNA methylome dynamics during differentiation from human monocytes to dendritic cells and macrophages identified gene sets undergoing dendritic-cell-specific or macrophage-specific demethylation. Demethylation is TET2-dependent and is essential for acquiring proper dendritic cell and macrophage identity. Most importantly, activation of the JAK3-STAT6 pathway, downstream of IL-4, is required for the acquisition of the dendritic-cell-specific demethylation and expression signature, following STAT6 binding. A constitutively activated form of STAT6 is able to bypass IL-4 upstream signalling and instruct dendritic-cell-specific functional DNA methylation changes. Conclusions: Our study is the first description of a cytokine-mediated sequence of events leading to direct gene-specific demethylation in innate immune cell differentiation., This work was supported by grant SAF2014-55942-R from the Instituto de Salud Carlos III, organism adscribed to the Ministerio de Economía y Competitividad and confunded by FEDER funds/ European Regional Development Fund (ERDF)- a way to build Europe and Innovation, and the EU FP7 306000 STATegra project. RVT is supported by a PFIS predoctoral fellowship.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Inflammatory cytokines and organ dysfunction associate with the aberrant DNA methylome of monocytes in sepsis

  • Lorente-Sorolla, Clara|||0000-0003-0404-9453
  • Garcia-Gomez, Antonio
  • Català-Moll, Francesc|||0000-0002-2354-8648
  • Toledano, Víctor
  • Ciudad, Laura|||0000-0002-5219-6792
  • Avendaño-Ortiz, José
  • Maroun-Eid, Charbel
  • Martín-Quirós, Alejandro
  • Martínez Gallo, Mónica|||0000-0002-7340-2161
  • Ruiz-Sanmartín, Adolfo|||0000-0001-5587-5419
  • del Campo, Álvaro García
  • Ferrer, Ricard|||0000-0002-4859-4747
  • Ruiz-Rodriguez, Juan Carlos|||0000-0001-7392-8617
  • Álvarez-Errico, Damiana|||0000-0002-7921-5164
  • Ballestar, Esteban|||0000-0002-1400-2440
Sepsis, a life-threatening organ dysfunction caused by a dysregulated systemic immune response to infection, associates with reduced responsiveness to subsequent infections. How such tolerance is acquired is not well understood but is known to involve epigenetic and transcriptional dysregulation. Bead arrays were used to compare global DNA methylation changes in patients with sepsis, non-infectious systemic inflammatory response syndrome, and healthy controls. Bioinformatic analyses were performed to dissect functional reprogramming and signaling pathways related to the acquisition of these specific DNA methylation alterations. Finally, in vitro experiments using human monocytes were performed to test the induction of similar DNA methylation reprogramming. Here, we focused on DNA methylation changes associated with sepsis, given their potential role in stabilizing altered phenotypes. Tolerized monocytes from patients with sepsis display changes in their DNA methylomes with respect to those from healthy controls, affecting critical monocyte-related genes. DNA methylation profiles correlate with IL-10 and IL-6 levels, significantly increased in monocytes in sepsis, as well as with the Sequential Organ Failure Assessment score; the observed changes associate with TFs and pathways downstream to toll-like receptors and inflammatory cytokines. In fact, in vitro stimulation of toll-like receptors in monocytes results in similar gains and losses of methylation together with the acquisition of tolerance. We have identified a DNA methylation signature associated with sepsis that is downstream to the response of monocytes to inflammatory signals associated with the acquisition of a tolerized phenotype and organic dysfunction.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

SIRT1/2 orchestrate acquisition of DNA methylation and loss of histone H3 activating marks to prevent premature activation of inflammatory genes in macrophages

  • Li, Tianlu|||0000-0001-7152-4870
  • Garcia-Gomez, Antonio
  • Morante-Palacios, Octavio|||0000-0002-6435-2756
  • Ciudad, Laura|||0000-0002-5219-6792
  • Özkaramehmet, S.
  • Van Dijck, E.
  • Rodríguez-Ubreva, Javier|||0000-0003-4707-4536
  • Vaquero, Alejandro|||0000-0002-8735-4156
  • Ballestar, Esteban|||0000-0002-1400-2440
Sirtuins 1 and 2 (SIRT1/2) are two NAD-dependent deacetylases with major roles in inflammation. In addition to deacetylating histones and other proteins, SIRT1/2-mediated regulation is coupled with other epigenetic enzymes. Here, we investigate the links between SIRT1/2 activity and DNA methylation in macrophage differentiation due to their relevance in myeloid cells. SIRT1/2 display drastic upregulation during macrophage differentiation and their inhibition impacts the expression of many inflammation-related genes. In this context, SIRT1/2 inhibition abrogates DNA methylation gains, but does not affect demethylation. Inhibition of hypermethylation occurs at many inflammatory loci, which results in more drastic upregulation of their expression upon macrophage polarization following bacterial lipopolysaccharide (LPS) challenge. SIRT1/2-mediated gains of methylation concur with decreases in activating histone marks, and their inhibition revert these histone marks to resemble an open chromatin. Remarkably, specific inhibition of DNA methyltransferases is sufficient to upregulate inflammatory genes that are maintained in a silent state by SIRT1/2. Both SIRT1 and SIRT2 directly interact with DNMT3B, and their binding to proinflammatory genes is lost upon exposure to LPS or through pharmacological inhibition of their activity. In all, we describe a novel role for SIRT1/2 to restrict premature activation of proinflammatory genes.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Understanding the relevance of DNA methylation changes in immune differentiation and disease

  • de la Calle-Fabregat, Carlos|||0000-0002-3026-3069
  • Morante-Palacios, Octavio|||0000-0002-6435-2756
  • Ballestar, Esteban|||0000-0002-1400-2440
Immune cells are one of the most complex and diverse systems in the human organism. Such diversity implies an intricate network of different cell types and interactions that are dependently interconnected. The processes by which different cell types differentiate from progenitors, mature, and finally exert their function requires an orchestrated succession of molecular processes that determine cell phenotype and function. The acquisition of these phenotypes is highly dependent on the establishment of unique epigenetic profiles that confer identity and function on the various types of effector cells. These epigenetic mechanisms integrate microenvironmental cues into the genome to establish specific transcriptional programs. Epigenetic modifications bridge environment and genome regulation and play a role in human diseases by their ability to modulate physiological programs through external stimuli. DNA methylation is one of the most ubiquitous, stable, and widely studied epigenetic modifications. Recent technological advances have facilitated the generation of a vast amount of genome-wide DNA methylation data, providing profound insights into the roles of DNA methylation in health and disease. This review considers the relevance of DNA methylation to immune system cellular development and function, as well as the participation of DNA methylation defects in immune-mediated pathologies, illustrated by selected paradigmatic diseases.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease

  • García Gómez, Antonio
  • Li, Tianlu|||0000-0001-7152-4870
  • de la Calle-Fabregat, Carlos|||0000-0002-3026-3069
  • Rodríguez-Ubreva, Javier|||0000-0003-4707-4536
  • Ciudad, Laura|||0000-0002-5219-6792
  • Català-Moll, Francesc|||0000-0002-2354-8648
  • Godoy-Tena, Gerard|||0000-0003-3832-5794
  • Martín Sánchez, Montserrat
  • San Segundo, Laura|||0000-0003-2391-5935
  • Muntión, Sandra|||0000-0001-7164-0767
  • Morales Urteaga, Xabier|||0000-0003-0303-9958
  • Ortiz de Solórzano, Carlos|||0000-0001-8720-0205
  • Oyarzabal, Julen|||0000-0003-1941-7255
  • San José Enériz, Edurne|||0000-0001-5786-5273
  • Esteller, M|||0000-0003-4490-6093
  • Agirre, Xabier|||0000-0002-6558-9560
  • Prosper, Felipe|||0000-0001-6115-8790
  • Garayoa, Mercedes|||0000-0003-2194-2841
  • Ballestar, Esteban|||0000-0002-1400-2440
Multiple myeloma (MM) progression and myeloma-associated bone disease (MBD) are highly dependent on bone marrow mesenchymal stromal cells (MSCs). MM-MSCs exhibit abnormal transcriptomes, suggesting the involvement of epigenetic mechanisms governing their tumor-promoting functions and prolonged osteoblast suppression. Here, we identify widespread DNA methylation alterations of bone marrow-isolated MSCs from distinct MM stages, particularly in Homeobox genes involved in osteogenic differentiation that associate with their aberrant expression. Moreover, these DNA methylation changes are recapitulated in vitro by exposing MSCs from healthy individuals to MM cells. Pharmacological targeting of DNMTs and G9a with dual inhibitor CM-272 reverts the expression of hypermethylated osteogenic regulators and promotes osteoblast differentiation of myeloma MSCs. Most importantly, CM-272 treatment prevents tumor-associated bone loss and reduces tumor burden in a murine myeloma model. Our results demonstrate that epigenetic aberrancies mediate the impairment of bone formation in MM, and its targeting by CM-272 is able to reverse MBD.